Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth

Cytokine

Volumn 53, Issue 2, 2011, Pages 115-129

  Saranadasa, Madhi ^a   Wang, Eunice S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Hypoxia; VEGF

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; BAY 43 6009; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYTARABINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY DC101; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLON TUMOR; COLORECTAL CANCER; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; THROMBOEMBOLISM; THYROID CANCER; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78651082550     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.06.012     Document Type: Review

References (176)

1. Nicosia R.F., Nicosia S.V., Smith M. Vascular endothelial growth factor, platelet derived growth factor, and insulin-like growth factor-I promote rat aortic angiogenesis in vitro. Am J Pathol 1994, 145:1023-1029.
2. Pepper M.S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogene activators and plasminogen-activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991, 181:902-906.
3. Melder R.J., Koenig G.C., Witwer B.P., Safabakhsh N., Munn L.L., Jain R.K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997.
4. Dvorak H.F., Flier J., Frank H. Tumors - wounds that do not heal - similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
5. Dvorak H.F., Harvey V.S., Estrella P., Brown L.F., McDonagh J., Dvorak A.M. Fibrin containing gels induce angiogenesis - implications for tumor stroma generation and wound healing. Lab Invest 1987, 57:673-686.
6. Wakui S., Furusato M., Itoh T., Sasaki H., Akiyama A., Kinoshita I., et al. Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastases - a morphometric study. J Pathol 1992, 168:257-262.
7. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
8. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 1992, 340:145-146.
9. Smithmccune K.K., Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994, 54:800-804.
10. Takebayashi Y., Akiyama S., Yamada K., Akiba S., Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996, 78:226-231.
11. Frank R.E., Saclarides T.J., Leurgans S., Speziale N.J., Drab E.A., Rubin D.B. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995, 222:695-699.
12. Tanigawa N., Amaya H., Matsumura M., Lu C.D., Kitaoka A., Matsuyama K., et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997, 57:1043-1046.
13. Tomisaki S., Ohno S., Ichiyoshi Y., Kuwano H., Maehara Y., Sugimachi K. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 1996, 77:1722-1728.
14. Choi H.J., Hyun M.S., Jung G.J., Kim S.S., Hong S.H. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998, 55:575-581.
15. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995, 36:127-137.
16. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
17. Kessler T., Fehrmann F., Bieker R., Berdel W.E., Mesters R.M. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets 2007, 8:257-268.
18. Dallas N.A., Fan F., Gray M.J., Van Buren G., Lim S.J., Xia L., et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev 2007, 26:433-441.
19. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
20. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
21. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2:673-682.
22. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cell secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
23. Folkman J., Bach M., Rowe J.W., Davidoff F., Lambert P., Hirsch C., et al. Tumor angiogenesis - therapeutic implications. N Engl J Med 1971, 285:1182.
24. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362:841-844.
25. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005, 333:328-335.
26. Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789-1797.
27. Melnyk O., Shuman M.A., Kim K.J. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996, 56:921-924.
28. Borgstrom P., Bourdon M.A., Hillan K.J., Sriramarao P., Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998, 35:1-10.
29. Borgstrom P., Hillan K.J., Sriramarao P., Ferrara N. Suppression of tumour angiogenesis by an anti-VEGF neutralising antibody. J Pathol 1996, 179:A21.
30. Presta L.G., Chen H., Oconnor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
31. Ferrer F.A., Miller L.J., Andrawis R.I., Kurtzman S.H., Albertsen P.C., Laudone V.P., et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997, 157:2329-2333.
32. Duque J.L.F., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54:523-527.
33. Reese D.M., Fratesi P., Corry M., Novotny W., Holmgren E., Small E.J. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001, 3:65-70.
34. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
35. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
36. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
37. Teicher B.A. A systems approach to cancer therapy (antiangiogenics plus standard cytotoxics→mechanism(s) of interaction). Cancer Metastasis Rev 1996, 15:247-272.
38. Borgstrom P., Gold D.P., Hillan K.J., Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999, 19:4203-4214.
39. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
40. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
41. Miller K.D., Wang M., Gralow J., Dickler M., Cobleigh M.A., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
42. Sandler A.B., Gray R., Brahmer J., Dowlati A., Schiller J.H., Perry M.C., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. Lung Cancer 2005, 49:S31.
43. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
44. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
45. Cassidy J., Tabernero J., Twelves C., Brunet R., Butts C., Conroy T., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004, 22:2084-2091.
46. Saltz Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study (vol. 26, p. 2013, 2008). J Clin Oncol 2008, 26:3110.
47. Kabbinavar F., Schulz J., McCleod M., Patel T., Hamm J., Hecht J., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
48. Negrier S., Lasset C., Escudier B., Grp Francais I. Cytokine therapy in metastatic renal cancer. N Engl J Med 1998, 339:851.
49. Atzpodien J., Korfer A., Palmer P.A., Franks C.R., Poliwoda H., Kirchner H. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha. Ann Oncol 1990, 1:377-378.
50. West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987, 316:898-905.
51. Escudier B., Bellmunt J., Negrier S., Melichar B., Bracarda S., Ravaud A., et al. Final results of the phase III randomized double-blind AVOREN trial of first-line bevacizumab (BEV)+interferon-alpha2a (IFN) in metastatic renal cell carcinoma. J Clin Oncol 2009, 27(Suppl.):15a. [abstr 5020].
52. Rini B., Halabi S., Rosenberg J., Stadler W., Vaena D., Atkins J., et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol 2009, 27(Suppl.):18s. [abstr LBA5019].
53. Hudis C. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005, 19(4 Suppl. 3):26-31.
54. Masood R., Cai J., Zheng T., Smith D., Hinton D., Gill P. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor positive tumors. Blood 2001, 98:1904-1913.
55. Kerbel R., Voloria-Petit A., Klement G., Rak J. "Accidental" anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000, 36:1248-1257.
56. Kerbel R.S. Molecular origins of cancer: tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
57. Ferrara N., DavisSmyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
58. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
59. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
60. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO(2) gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
61. Baish J.W., Jain R.K. Fractals and cancer. Cancer Res 2000, 60:3683-3688.
62. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
63. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-1380.
64. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Cancer cells compress intratumour vessels. Nature 2004, 427:695.
65. Boucher Y., Jain R.K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors - implications for vascular collapse. Cancer Res 1992, 52:5110-5114.
66. Netti P.A., Roberge S., Boucher Y., Baxter L.T., Jain R.K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996, 52:27-46.
67. Wildiers H., Guetens G., De Boeck G., Verbeken E., Landuyt B., Landuyt W., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II. Br J Cancer 2003, 88:1979-1986.
68. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
69. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
70. Stoeltzing O., Ahmad S.A., Liu W.B., McCarty M.F., Wey J.S., Parikh A.A., et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003, 63:3370-3377.
71. Jain R.K., Booth M.F. What brings pericytes to tumor vessels?. J Clin Invest 2003, 112:1134-1136.
72. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277:48-50.
73. Thurston G., Suri C., Smith K., McClain J., Sato T.N., Yancopoulos G.D., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514.
74. Jain R.K., Munn L.L. Leaky vessels? Call Angl1!. Nat Med 2000, 6:131-132.
75. Baluk P., Morikawa S., Haskell A., Mancuso M., McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003, 163:1801-1815.
76. Hall E.J. Radiation, the two-edged sword: cancer risks at high and low doses. Cancer J 2000, 6:343-350.
77. Rampling R., Cruickshank G., Lewis A.D., Fitzsimmons S.A., Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994, 29:427-431.
78. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005, 11:743-750.
79. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
80. Shaked Y., Kerbel R.S. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007, 67:7055-7058.
81. Gordon M.S., Margolin K., Talpaz M., Sledge G.W., Holmgren E., Benjamin R., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
82. Senger D.R. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell 2010, 21:377-379.
83. Baffert F., Thurston G., Rochon-Duck M., Le T., Brekken R., McDonald D.M. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 2004, 94:984-992.
84. Wilhelm S.M., Carter C., Tang L.Y., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
85. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
86. Ciuffreda L., McCubrey J.A., Milella M. Signaling intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK pathways) as therapeutic targets for anti-cancer and anti-angiogenesis treatments. Curr Signal Transduction Ther 2009, 4:130-143.
87. Alavi A., Hood J.D., Frausto R., Stupack D.G., Cheresh D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301:94-96.
88. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
89. Kimura E.T., Nikiforova M.N., Zhu Z.W., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
90. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. In: Soc Endocrinology; 2001. p. 219-25.
91. Wilhelm S., Chien D.S. BAY 43-9006: preclinical data. Curr Pharm Des 2002, 8:2255-2257.
92. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFR beta(+) perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7:870-879.
93. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., et al. Identification of the von-Hippel Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
94. Patel P.H., Chadalavada R.S.V., Chaganti R.S.K., Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006, 12:7215-7220.
95. Chang Y.S., Adnane J., Trail P.A., Levy J., Henderson A., Xue D.H., et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007, 59:561-574.
96. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
97. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
98. Llovet J.M., Bruix J. Barcelona Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
99. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
100. Semela D., Dufour J.F. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004, 41:864-880.
101. Tseng P.L., Tai M.H., Huang C.C., Wang C.C., Lin J.W., Hung C.H., et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 2008, 98:349-357.
102. Wada H., Nagano H., Yamamoto H., Yang Y.B., Kondo M., Ota H., et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 2006, 26:414-423.
103. Poon R.T.P., Ho J.W.Y., Tong C.S.W., Lau C., Ng I.O.L., Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91:1354-1360.
104. Liu L., Cao Y.C., Chen C., Zhang X.M., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
105. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. In: Massachusetts Medical Soc; 2008. p. 378-90.
106. Murphy D.A., Makonnen S., Lassoued W., Feldman M.D., Carter C., Lee W.M.F. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006, 169:1875-1885.
107. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
108. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
109. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1998, 41:2588-2603.
110. Mendel D.B., Laird A.D., Xin X.H., Louie S.G., Christensen J.G., Li G.M., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
111. Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. In: Antiangiogenic agents in cancer therapy. Cancer drug discovery and development series, vol. 3; 1999. p. 119-41.
112. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
113. Morimoto A.M., Tan N., West K., McArthur G., Toner G.C., Manning W.C., et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 2004, 23:1618-1626.
114. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
115. Drevs J. Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Res 2003, 23:1159-1161.
116. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
117. Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
118. Dal Lago L., D'Hondt V., Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008, 13:845-858.
119. Vincent P., Zhang X., Chen C. Chemotherapy with the raf kinase inhibitor BAY 43-9006 in combination with irinotecan, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenograft models. Proc Am Soc Clin Oncol 2002, 21.
120. Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose escalation study. Lung Cancer 2010 [Epub ahead of print].
121. Kozloff M., Chuang E., Starr A., Gowland P.A., Cataruozolo P.E., Collier M., et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2009.
122. Zhou Q., Guo P., Gallo J.M. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008, 14:1540-1549.
123. Zhou Q., Gallo J.M. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol 2009, 11:301-310.
124. Kamoun W.S., Ley C.D., Farrar C.T., Duyverman A.M., Lahdenranta J., Lacorre D.A., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27:2542-2552.
125. Sorensen A.G., Batchelor T.T., Zhang W.T., Chen P.J., Yeo P., Wang M.Y., et al. A "Vascular Normalization Index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69:5296-5300.
126. Batchelor T.T., Duda D.G., di Tomaso E., Ancukiewicz M., Plotkin S.R., Gerstner E., et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010.
127. Yoon S.S., Stangenberg L., Lee Y.J., Rothrock C., Dreyfuss J.M., Baek K.H., et al. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009, 74:1207-1216.
128. Schueneman A.J., Himmelfarb E., Geng L., Tan J.H., Donnelly E., Mendel D., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003, 63:4009-4016.
129. Cannistra S.A. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008, 26:3665-3667.
130. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. In: Amer Soc Clinical Oncology; 2008. p. 3709-14.
131. Feldman D.R., Baum M.S., Ginsberg M.S., Hassoun H., Flombaum C.D., Velasco S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
132. Bose D., Meric-Bernstam F., Hofstetter W., Reardon D.A., Flaherty K.T., Ellis L.M. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010, 11:373-382.
133. Karp J.E., Gojo I., Pili R., Gocke C.D., Greer J., Guo C., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004, 10:3577-3585.
134. Zahiragic L., Schliemann C., Bieker R., Thoennissen N.H., Burow K., Kramer C., et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007, 21:1310-1312.
135. Mori S., Cortes J., Kantarjian H., Zhang W., Andreef M., Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008, 49:2246-2255.
136. Ravandi F., Cortes J.E., Jones D., Faderl S., Garcia-Manero G., Konopleva M.Y., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28:1856-1862.
137. Lal D, Park J, Demock K, Marinaro J, Perez A, Lin M-H, et al. Aflibercept exerts anti-vascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molec Cancer Therap 2010, in press.
138. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
139. Ebos J.M., Lee C.R., Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009, 15:5020-5025.
140. Wolmark N., Yothers G., O'Connell M., Sharif S., Atkins J., Seay T., et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009, 27.
141. Patel J.D., Hensing T.A., Rademaker A., Hart E.M., Blum M.G., Milton D.T., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009, 27:3284-3289.
142. Penson R.T., Dizon D.S., Cannistra S.A., Roche M.R., Krasner C.N., Berlin S.T., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010, 28:154-159.
143. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., DiBartolomeo M., et al. XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
144. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
145. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85:1301-1307.
146. Baccala A., Hedgepeth R., Kaouk J., Magi-Galluzzi C., Gilligan T., Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007, 14:1095-1097.
147. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
148. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
149. Gort E.H., Groot A.J., van der Wall E., van Diest P.J., Vooijs M.A. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 2008, 8:60-67.
150. Sullivan R., Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007, 26:319-331.
151. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
152. Bergers G., Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
153. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
154. Ebos J.M.L., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007, 104:17069-17074.
155. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
156. Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009, 55:1430-1439.
157. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3:1222-1227.
158. Bertolini F. Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology. Breast 2009, 18(Suppl. 3):S48-S50.
159. Burstein H.J., Chen Y.H., Parker L.M., Savoie J., Younger J., Kuter I., et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008, 14:7871-7877.
160. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
161. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group study. Clin Can Res 2008, 14:1407-1412.
162. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
163. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
164. Norden-Zfoni A., Desai J., Manola J., Beaudry P., Force J., Maki R., et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007, 13:2643-2650.
165. Azad N.S., Aragon-Ching J.B., Dahut W.L., Gutierrez M., Figg W.D., Jain L., et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:1411-1416.
166. Izzedine H., Ederhy S., Goldwasser F., Soria J.C., Milano G., Cohen A., et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807-815.
167. Yao J.C., Phan A., Hoff P.M., Chen H.X., Charnsangavej C., Yeung S.C.J., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 2008, 26:1316-1323.
168. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30:117-124.
169. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
170. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
171. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:650-656.
172. Jonasch E., Corn P., Pagliaro L.C., Warneke C.L., Johnson M.M., Tamboli P., et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010, 116:57-65.
173. Richly H, Kupsch P, Passarge K, Grubert M, Hilger RA, Haase CG, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors. In: Amer Soc Clinical Oncology; 2004. p. 3049.
174. Siu L.L., Awada A., Takimoto C.H., Piccart M., Schwartz B., Giannaris T., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Can Res 2006, 12:144-151.
175. Faivre S., Raymond E., Boucher E., Douillard J., Lim H.Y., Kim J.S., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10:794-800.
176. Wallace JA, Locker G, Nattam S, Kasza K, Wade-Oliver K, Vokes EE, et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2007; A-137.